GPI-PLD Antibodies

Santa Cruz Biotechnology delivers a wide array of GPI-PLD monoclonal antibodies for research focused on glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD). GPI-PLD Antibodies are available for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). GPI-PLD is a crucial enzyme that hydrolyzes glycosylphosphatidylinositol (GPI)-anchored proteins, playing a significant role in cell signaling and membrane dynamics. The enzyme's activity is essential for releasing bioactive molecules, which influence processes such as cell adhesion, migration, and immune response. GPI-PLD research has revealed important implications in various diseases, including cancer and neurodegenerative disorders. Investigating GPI-PLD expression patterns and interactions provides valuable insights into cellular pathways and disease mechanisms. Understanding GPI-PLD function continues to advance knowledge in cell biology and disease progression. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of GPI-PLD's role in health and disease.